The Health Technology Assessment (HTA) intends to review the efficacy, safety, cost-effectiveness and budgetary impact of the use of vitamin D testing in risk groups as defined by the Swiss Federal Nutrition Commission (people with bone disease, older adults, obese individuals, pregnant women, people with dark skin and athletes). It will also analyse evidence regarding the clinical effects of vitamin D supplementation in these risk groups. The feasibility of a full HTA has been determined on the basis of the scoping report. A full HTA is not justified at this stage, as no clinical studies are available that would enable evaluation of vitamin D tests. This issue could be revisited once such studies are available.